Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system
Authors:
- Daniel R. CroftDCDaniel R. Croft
- Rothwelle J. TateRTRothwelle J. Tate
- Kevin M. RyanKRKevin M. Ryan
- Christine DufèsChristine Dufès
- 1 March 2012
- journal article
- Published by Elsevier in Biomaterials
- Vol. 33 (9) , 2701-2709
Abstract
No abstract availableKeywords
Funding Information
- Medical Research Scotland
- The IVIS (No. ME0442)
- Cancer Research UK
- The Association for International Cancer Research
This publication has 26 references indexed in Scilit:
- Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administrationJournal of Controlled Release, 2011
- Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNAJournal of Controlled Release, 2010
- Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesiclesJournal of Controlled Release, 2009
- Transferrin receptor 2 is frequently expressed in human cancer cell linesBlood Cells, Molecules, and Diseases, 2007
- A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivoJournal of Clinical Investigation, 2007
- Synthetic Anticancer Gene Medicine Exploits Intrinsic Antitumor Activity of Cationic Vector to Cure Established TumorsCancer Research, 2005
- Anticancer Drug Delivery with Transferrin Targeted Polymeric Chitosan VesiclesPharmaceutical Research, 2004
- p73, the “Assistant” Guardian of the Genome?Annals of the New York Academy of Sciences, 2003
- Tumor-targeted gene delivery of tumor necrosis factor-α induces tumor necrosis and tumor regression without systemic toxicityCancer Gene Therapy, 2002
- Synthetic DNA delivery systemsNature Biotechnology, 2000